Literature DB >> 17627032

Brain tumor formation in tuberous sclerosis depends on Erk activation.

Jaroslaw Jozwiak1, Wieslawa Grajkowska, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Zalewski, Agnieszka Zajaczkowska, Marcin Roszkowski, Artur Slupianek, Pawel Wlodarski.   

Abstract

Tuberous sclerosis (TS) is an autosomal dominant disease associated with the formation of usually benign tumors or hamartomas. The disease is connected with upregulation of mammalian target of rapamycin, central regulator of protein translation, which is usually regarded to be activated by Akt kinase. Here, we show for the first time that in all four brain lesions and one angiomyolipoma from TS patients both extracellular signal-regulated kinase (Erk) and p90 ribosomal S6 kinase 1 activation as well as Erk-dependent phosphorylation of p70 ribosomal S6 kinase 1 are markedly elevated whereas Akt, participating in the classical pathway of mammalian target of rapamycin activation is not always activated. Erk activation is also present in TS-derived cell lines. Importantly, Erk inhibition leads to the decrease of proliferation potential of such lines. These results show that Erk is specifically implicated in the pathogenesis of hamartomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627032     DOI: 10.1007/bf02685886

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  34 in total

1.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

2.  Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.

Authors:  E P Henske; L L Wessner; J Golden; B W Scheithauer; A O Vortmeyer; Z Zhuang; A J Klein-Szanto; D J Kwiatkowski; R S Yeung
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Rheb binds and regulates the mTOR kinase.

Authors:  Xiaomeng Long; Yenshou Lin; Sara Ortiz-Vega; Kazuyoshi Yonezawa; Joseph Avruch
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

4.  Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.

Authors:  Xuesong Liu; Jessica Powlas; Yan Shi; Anatol X Oleksijew; Alexander R Shoemaker; Ron De Jong; Tilman Oltersdorf; Vincent L Giranda; Yan Luo
Journal:  Anticancer Res       Date:  2004 Sep-Oct       Impact factor: 2.480

5.  Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.

Authors:  Han C Dan; Mei Sun; Lin Yang; Richard I Feldman; Xue-Mei Sui; Chien Chen Ou; Mark Nellist; Raymond S Yeung; Dicky J J Halley; Santo V Nicosia; Warren J Pledger; Jin Q Cheng
Journal:  J Biol Chem       Date:  2002-07-11       Impact factor: 5.157

6.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

7.  Subependymal giant cell astrocytoma with positive tuberin expression--case report.

Authors:  Sadaharu Tabuchi; Haruo Takigawa; Akira Oka; Masashi Mizuguchi; Yasushi Horie; Takashi Watanabe
Journal:  Neurol Med Chir (Tokyo)       Date:  2003-12       Impact factor: 1.742

8.  AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Authors:  Joseph F Gera; Ingo K Mellinghoff; Yijiang Shi; Matthew B Rettig; Chris Tran; Jung-hsin Hsu; Charles L Sawyers; Alan K Lichtenstein
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

9.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Authors:  Philippe P Roux; Bryan A Ballif; Rana Anjum; Steven P Gygi; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

10.  Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase.

Authors:  Jason A Lehman; Victor Calvo; Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2003-05-11       Impact factor: 5.157

View more
  7 in total

1.  Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.

Authors:  Vinit V Patil; Miguel Guzman; Angela N Carter; Geetanjali Rathore; Daniel Yoshor; Daniel Curry; Angus Wilfong; Satish Agadi; John W Swann; Adekunle M Adesina; Meenakshi B Bhattacharjee; Anne E Anderson
Journal:  Neuropathology       Date:  2015-09-18       Impact factor: 1.906

2.  Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.

Authors:  Magdalena Ewa Tyburczy; Katarzyna Kotulska; Piotr Pokarowski; Jakub Mieczkowski; Joanna Kucharska; Wieslawa Grajkowska; Maciej Roszkowski; Sergiusz Jozwiak; Bozena Kaminska
Journal:  Am J Pathol       Date:  2010-02-04       Impact factor: 4.307

Review 3.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

Review 4.  The pathogenesis and imaging of the tuberous sclerosis complex.

Authors:  Henry J Baskin
Journal:  Pediatr Radiol       Date:  2008-04-15

5.  Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.

Authors:  Paola Zordan; Manuela Cominelli; Federica Cascino; Elisa Tratta; Pietro L Poliani; Rossella Galli
Journal:  J Clin Invest       Date:  2018-03-12       Impact factor: 14.808

6.  Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations.

Authors:  Anika Bongaarts; Krinio Giannikou; Roy J Reinten; Jasper J Anink; James D Mills; Floor E Jansen; G M Wim Spliet; Willfred F A den Dunnen; Roland Coras; Ingmar Blümcke; Werner Paulus; Theresa Scholl; Martha Feucht; Katarzyna Kotulska; Sergiusz Jozwiak; Anna Maria Buccoliero; Chiara Caporalini; Flavio Giordano; Lorenzo Genitori; Figen Söylemezoğlu; José Pimentel; Mark Nellist; Antoinette Y N Schouten-van Meeteren; Anwesha Nag; Angelika Mühlebner; David J Kwiatkowski; Eleonora Aronica
Journal:  Oncotarget       Date:  2017-09-08

7.  Hyperactivation of mTORC1 in a double hit mutant zebrafish model of tuberous sclerosis complex causes increased seizure susceptibility and neurodevelopmental abnormalities.

Authors:  Ann-Sofie De Meulemeester; Lise Heylen; Aleksandra Siekierska; James D Mills; Alessia Romagnolo; Nicole N Van Der Wel; Eleonora Aronica; Peter A M de Witte
Journal:  Front Cell Dev Biol       Date:  2022-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.